Pfizer on track to post best monthly gain in nearly three decades
https://seekingalpha.com/news/3775524-pfizer-on-track-to-post-best-monthly-gain-in-nearly-three-decades
1 reply
Despite a threat to vaccine-driven immunity with the recent emergence of the new COVID-19 variant Omicron, Pfizer (PFE +2.4%) is on course to record its best monthly gain since Dec. 1991.
Over the past 12 months, the shares of the New York-based pharma giant has climbed ~40.8% well outperforming the broader index, as indicated in the graph below. Driven by the sales of the vaccine it co-developed with BioNTech (NASDAQ:BNTX), its revenue has more than doubled over the past year.
Pfizer’s (NYSE:PFE) today’s performance contrasts with rival vaccine maker Moderna (MRNA -4.0%) whose CEO has warned that the COVID-19 vaccines could lose efficacy against Omicron, classified by the World Health Organization (WHO) as a global variant of concern.
However, Pfizer (PFE) targets both preventative and therapeutic aspects of the disease with its vaccine and the experimental COVID-19 pill Paxlovid, for which the company has already sought U.S. regulatory authorization.